EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy

Paula Ogrodnik, Eric Anderson, Nicholas Gloude, Deborah Schiff iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32013 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Paula Ogrodnik and 3 co-authors. Institution: Division of Pediatric Hematology/Oncology, Rady Children's Hospital San Diego, San Diego, California, USA. Major MEDLINE topics: Inotuzumab Ozogamicin, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Immunotherapy, Adoptive, Antineoplastic Agents, Immunological. 10 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We retrospectively analyzed outcomes for nine children and young adults who were treated with inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) B‐acute lymphoblastic leukemia (ALL) after CD19‐chimeric antigen receptor T‐cell therapy (CART). After InO cycle 1, overall response rate was 77.8%; 66.7% achieved measurable residual disease (MRD)‐negative remission. One‐year event‐free survival (EFS) was 37.5%; 1‐year overall survival (OS) was 50%; 2‐year EFS was 37.5%; 2‐year OS was 37.5%. Median survivor follow‐up is 2.9 years (0.5–4.7). Significant adverse events included prolonged cytopenias, hepatotoxicity, and post‐transplant sinusoidal obstructive sydrome. InO showed promising efficacy as treatment for children and young adults with R/R B‐ALL after CD19‐CART. Extramedullary disease prior to InO and positive MRD after InO cycle 1 were associated with poor outcomes.

Subjects

MeSH terms (MEDLINE)

Inotuzumab OzogamicinPrecursor B-Cell Lymphoblastic Leukemia-LymphomaImmunotherapy, AdoptiveAntineoplastic Agents, ImmunologicalNeoplasm Recurrence, LocalReceptors, Chimeric AntigenHumansChildMaleFemaleAdolescentYoung AdultRetrospective StudiesChild, PreschoolAdultAntigens, CD19Survival RateFollow-Up StudiesPrognosis

Author keywords

chimeric antigen receptor therapyimmunotherapyinotuzumab ozogamicinprecursor B‐cell lymphoblastic leukemiarelapse

Substances

Inotuzumab OzogamicinAntigens, CD19Antineoplastic Agents, ImmunologicalReceptors, Chimeric Antigen

Authors and institutions

  • Division of Pediatric Hematology/Oncology, Rady Children's Hospital San Diego, San Diego, California, USA.
  • Department of Pediatrics, University of California San Diego, San Diego, California, USA.

ORCID profiles: Deborah Schiff

Cite

APA

Ogrodnik, P., Anderson, E., Gloude, N., & Schiff, D. (2025). Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32013

Vancouver

Ogrodnik P, Anderson E, Gloude N, Schiff D. Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32013

BibTeX
@article{Ogrodnik2025,
  author = {Ogrodnik, Paula and Anderson, Eric and Gloude, Nicholas and Schiff, Deborah},
  title = {Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32013}
}
Start for free →